AstraZeneca, a leading global science-led biopharmaceutical company of Swedish-British origin, announced its partnership with MGH Healthcare Limited to provide convenient and reliable access to AstraZeneca medicines in Bangladesh — says a press release.
The panel session on “Driving access to innovative medicines to improve patient outcomes in Bangladesh”, was hosted by Business Sweden — The Swedish Trade and Invest Council in Dhaka.
Swedish Ambassador Charlotta Schlyter and British High Commissioner Robert Chatterton Dickson delivered remarks on the potential for further healthcare cooperation with Bangladesh.
AstraZeneca is a leader in the treatment of Non-Communicable Diseases (NCDs) such as Cancer and Cardiovascular-Metabolic-Renal Diseases which are prevalent in Bangladesh.
“AstraZeneca is committed to improve patient outcomes through scientific discovery and collaborations,” said Nitin Kapoor, Company President AstraZeneca.